Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
- PMID: 24187498
- PMCID: PMC3810342
- DOI: 10.2147/NDT.S49895
Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
Abstract
Under normal conditions, the adult human brain is fueled primarily by glucose. A prominent feature of Alzheimer's disease (AD) is region-specific decreases in cerebral glucose metabolism. Ketone bodies are a group of compounds produced from fat stores during periods of low glucose availability that can provide an alternative to glucose for brain metabolism. Consumption of sufficient quantities of caprylic triglyceride (CT) increases plasma concentrations of ketone bodies and may be beneficial in conditions of compromised glucose metabolism, such as AD. The present study describes the use of CT in mild-to-moderate AD in routine clinical practice. Case records from eight patients with extensive monitoring of cognitive function using the Mini-Mental State Examination (MMSE) and who had received CT for ≥6 months were reviewed. All were outpatients aged ≥50 years, cared for in standard practice, had a diagnosis of probable AD of mild-to-moderate severity (MMSE 14-24), and had received CT for at least 6 months in addition to other approved pharmacotherapy for AD. Response to CT administration as measured by MMSE scores varied by patient. However, the rate of decline in MMSE scores appeared slower than previously published reports for patients treated with pharmacotherapy alone. Profiling of individual patients may provide insight regarding those most likely to benefit from addition of CT to currently approved AD pharmacotherapy.
Keywords: Alzheimer’s disease; cognition; glucose; ketosis; metabolism.
Figures


Similar articles
-
Effects of caprylic triglyceride on cognitive performance and cerebral glucose metabolism in mild Alzheimer's disease: a single-case observation.Front Aging Neurosci. 2014 Jul 16;6:133. doi: 10.3389/fnagi.2014.00133. eCollection 2014. Front Aging Neurosci. 2014. PMID: 25076901 Free PMC article.
-
Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer's disease.Neuropsychiatr Dis Treat. 2013;9:1619-27. doi: 10.2147/NDT.S52331. Epub 2013 Oct 23. Neuropsychiatr Dis Treat. 2013. PMID: 24187497 Free PMC article.
-
Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study.Clin Interv Aging. 2016 Jan 8;11:29-36. doi: 10.2147/CIA.S95362. eCollection 2016. Clin Interv Aging. 2016. PMID: 26811674 Free PMC article. Clinical Trial.
-
The Ketogenic Diet and Alzheimer's Disease.J Nutr Health Aging. 2022;26(6):606-614. doi: 10.1007/s12603-022-1807-7. J Nutr Health Aging. 2022. PMID: 35718870 Review.
-
Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease.Ann N Y Acad Sci. 2016 Mar;1367(1):12-20. doi: 10.1111/nyas.12999. Epub 2016 Jan 14. Ann N Y Acad Sci. 2016. PMID: 26766547 Review.
Cited by
-
Lauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pathogenicity.Open Heart. 2016 Jul 27;3(2):e000467. doi: 10.1136/openhrt-2016-000467. eCollection 2016. Open Heart. 2016. PMID: 27547436 Free PMC article. Review.
-
Association of Circulating Caprylic Acid with Risk of Mild Cognitive Impairment and Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort.J Prev Alzheimers Dis. 2023;10(3):513-522. doi: 10.14283/jpad.2023.37. J Prev Alzheimers Dis. 2023. PMID: 37357292 Free PMC article.
-
A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease.Heliyon. 2023 Nov 15;9(11):e22483. doi: 10.1016/j.heliyon.2023.e22483. eCollection 2023 Nov. Heliyon. 2023. PMID: 38074891 Free PMC article. Review.
-
Medium-Chain Triglycerides (MCTs) for the Symptomatic Treatment of Dementia-Related Diseases: A Systematic Review.J Nutr Metab. 2024 Apr 12;2024:9672969. doi: 10.1155/2024/9672969. eCollection 2024. J Nutr Metab. 2024. PMID: 38715705 Free PMC article. Review.
References
-
- Alzheimer’s Association . 2012 Alzheimer’s Disease Facts and Figures. Chicago, IL: Alzheimer’s Association; 2012. - PubMed
-
- US Food and Drug Administration Guidance for Industry: Frequently Asked Questions About Medical Foods 2007Available from: http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryin...Accessed March 16, 2013
-
- Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement. 2010;6(1):1–10. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources